Alkaline citrate

Phase 3Small molecule

UUniversity of Cologne

Alkaline citrate is one of 5 small molecule programs targeting Calcinosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CalcinosisActive, not recruiting

CalcinosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Calcinosis

#DrugCompanyPhaseTrials

Potassium Iodide

DDawnrays Pharmaceutical (Holdings) Limited

Phase 3

1 2

Sodium Thiosulfate

HHope Pharmaceuticals

Phase 2

4 3

Calcitonin

TTarsa Therapeutics, Inc.

Phase 2

1 4

Alkaline citrate

UUniversity of Cologne

Phase 3

1 5

Inomax

MMallinckrodt

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Calcinosis1 trial

Alkaline Citrate Treatment to Lower the Risk of Nephrocalcinosis in Preterm Infants

Completed·UUniversity of Cologne·Phase 3·NCT00249951·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Alkaline citrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Alkaline citrate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Alkaline citrate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Cologne company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Cologne

Alkaline citrate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Calcinosis1 trial

References

Drug Info

Quick Facts

Related News